WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET.In addition to discussing third quarter 2025 financial results, the Investor Day will feature:An in-depth look into the Company's strategy for long-term, sustained growth for ZORYVE® (roflumilast)A detailed review of clinical development activities and advancements for new ZORYVE indications and ARQ-234An overview of the Company's capital allocation strategy and financial outlookThe event will feature presentations from Arcutis Biotherapeutics' management team as well as a fireside chat with Douglas DiRuggiero, PA-C, DMSc, founding president of the Georgia Dermatology Physician Assistant Society.Following formal presentations, management will host a Q&A session.A live webcast of the event and the presentation materials will be available on the "Events" section of ...Full story available on Benzinga.com